LYAR

Across TCGA pan-cancer cohorts, LYAR mass-spec protein is linked to patient survival in 7 of 34 cancer types, making it a survival-associated LYAR data layer compared with 30 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher LYAR mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated LYAR expression acts as an unfavorable survival marker, although some lineages such as LSCC and UCEC show a favorable association.

CCRCC, PDAC, and LUAD are the cancer types where LYAR mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Median	All	0.592	0.883	<.001	70	view →
PDAC	DFS	Quartile	II,III,IV	0.266	0.491	.005	39	view →
LUAD	DFS	Tertile	All	0.601	0.919	.018	10	view →
HNSC	DFS	Tertile	All	0.915	1.000	.008	10	view →
LSCC	DFS	Median	All	0.929	0.575	.008	9	view →
UCEC	DFS	Quartile	III,IV	1.000	0.310	.027	8	view →
GBM	DFS	Tertile	All	0.266	0.469	.014	5	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

LYAR–CCRCC (DFS)

Open the CCRCC breakdown →